Intelligence Feed event · Capital · 2026-09-20

    Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347M

    Question

    Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347M

    Direct answer

    Electra Therapeutics announced terms for its Nasdaq initial public offering, offering 21.7 million shares in an indicative price band of $14 to $16 per share. At the top of the range, the transaction will generate gross proceeds of $347 million. The capital proceeds will primarily support the advancement of lead asset ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-20
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347M”, revision 1, evidence through 2026-09-20. https://marketontology.com/market-events/2026-09-20/electra-therapeutics-sets-nasdaq-ipo-terms-to-raise-up-to-347m-43397f

    CAPITAL
    Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347M
    Electra Therapeutics announced terms for its Nasdaq initial public offering, offering 21.7 million shares in an indicative price band of $14 to $16 per share. At the top of the range, the transaction will generate gross proceeds of $347 million. The capital proceeds will primarily support the advancement of lead asset ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis.
    ETRAJEF
    Impact
    62
    SEP 20
    SIG
    88%
    ETRAJEF
    Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347M
    Electra Therapeutics announced terms for its Nasdaq initial public offering, offering 21.7 million shares in an indicative price band of $14 to $16 per share. At the top of the range, the transaction will generate gross proceeds of $347 million. The capital proceeds will primarily support the advancement of lead asset ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis.
    → Primary clinical biotech issuance absorbs institutional liquidity while pricing establishes valuation comps for early-stage antibody therapeutics.
    Impact
    Electra Therapeutics announced terms for its Nasdaq initial public offering, offering 21.7 million shares in an indicative price band of $14 to $16 per share. At the top of the range, the transaction will generate gross proceeds of $347 million. The capital proceeds will primarily support the advancement of lead asset ipsoprubart through the SURPASS registration trial, targeting secondary haemophagocytic lymphohistiocytosis.
    Affected
    ETRAJEF
    Transmission
    Primary clinical biotech issuance absorbs institutional liquidity while pricing establishes valuation comps for early-stage antibody therapeutics.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ETRAprimary market equity issuance and initial trading liquidityWatch1-5d21.7M share IPO pricing between $14 and $16 under ticker ETRA
    JEFECM underwriting fee realizationUp1-4wUnderwriter on up to $347M healthcare initial public offering

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month